|연구실 전화번호||02 - 2220 - 2468|
|학교 이메일 주소firstname.lastname@example.org|
|학사학위 취득 관련 사항||College of Medicine, Yonsei University (2001, MD)|
|석사학위 취득 관련 사항|
|박사학위 취득 관련 사항||Nanoscience and Technology, Yonsei University (2006, PhD)|
2011 - Present: Assistant Professor, Graduate School of Biomedical Science and Engineering, Hanyang University
2010 – 2011: Assistant professor, Department of Applied Bioscience, CHA University
2008 - 2010: Postdoctoral Fellow, Emory University School of Medicine, Atlanta, GA, USA
|실험실 명 (국문)||줄기세포 재생의학 연구실|
|실험실 명 (영문)||Laboratory of Stem Cell Biology and Regenerative M|
|Research interest||Our lab’s research aims to develop novel therapies that regenerate damaged and diseased tissues by harnessing stem or progenitor cells and/or biomaterials.
A stem cell is currently defined as a cell that can continuously produce unaltered daughters (self-renewal activity) and also has the ability to produce daughter cells that have different, more restricted properties (Figure 1). Recently, growing numbers of reports suggest that introducing and/or inducing ectopic expression of several specific transcription factors or microRNAs, or the addition of other small molecules, can convert one differentiated cell type to another. The ability to reliably induce cell type conversion has enormous implications: converted cells can be used to investigate disease pathophysiology, screen drugs, and develop regenerative protocols for damaged tissues. Our lab is currently screening for transcription factors, microRNAs, and small molecules that can be utilized to direct this cell type change (Figure 2).
We are also working on targeted genetic modification of stem cells, converted cells, and progenitor cells to correct abnormal pathological genes and to investigate the function of genes. Previous attempts at gene therapy have often failed due to tumor generation caused by random integration of transgenes. Targeted gene therapy avoids the tumorigenesis caused by random integration events, providing a novel approach to therapeutic manipulation of gene expression for many diseases.
In addition to the cells, we use biocompatible biomaterials to enhance tissue regeneration by providing controlled environment for the cells. The combination of stem cells with biomaterials often shows better tissue regeneration than the stem cells alone.
The progress of biomedical research benefits from networking and cooperation, and we are enthusiastic about corroborating with other labs.
Open opportunities: Undergraduate students, graduate students, or doctors who are interested in our studies, are invited to inquire about opportunities to work together in this exciting research.
실험실에서 하는 연구에 관심있는 학생들 (대학재학생, 졸업생, 대학원재학생, 대학원 졸업생)이나 postdoc은 이메일이나 전화를 통해 연락 주시기 바랍니다.
Kim H, Cho HJ, Kim SW, Liu B, Choi YJ, Lee JY, Sohn YD, Yoon YS. CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow: novel role of non-endothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease. Circ. Res. (IF: 9.214) 2010 Sep 3; 107: 602-614
Kim H, Park JS, Choi YJ, Kim MO, Huh YH, Kim SW, Han JW, Lee JY, Kim S, Houge MA, Ii M, Yoon YS. Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy. Stem Cells. (IF: 7.747) 2009 Jul; 27(7): 1686-1696
Kim H, Kim SW, Nam D, Kim S, Yoon YS. Cell therapy with bone marrow cells for myocardial regeneration. Antioxid Redox Signal. (IF: 7.581) 2009 Augt; 11(8): 1897-1911
Kim H, Choi JY, Lee JM, Park YS, Suh H, Song HR, Jo SA, Jo I. Dexamethasone increases angiopoietin-1 and quiescent hematopoietic stem cells: A novel mechanism of dexamethasone-induced hematoprotection. FEBS Lett. (IF: 3.264) 2008 Oct 15;582(23-24):3509-3514
Kim H, Lee JM, Park JS, Jo SA, Kim YO, Kim CW, Jo I. Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem Biophys Res Commun. (IF: 2.648) 2008 Jul 18;372(1):243-248
|연구 분야 대표 그림|